Skip to main content
. Author manuscript; available in PMC: 2014 Mar 14.
Published in final edited form as: Antibodies (Basel). 2012 Jul 4;1(2):149–171. doi: 10.3390/antib1020149

Figure 2.

Figure 2

Efficacy of hu14.18-IL2 therapy is influenced by the timing of its initiation. Groups of 4 mice were treated IV with 5µg/d X 5d of hu14.18-IL2 beginning on d 5, 7, 9 or 11 following IV injection of 5 × 105 NXS2 NB cells (or IV PBS). Mice were sacrificed on d28 and the liver metastases were enumerated. Data are mean ± SE (adapted from Neal et al, 2004 [39]).